Semaglutide

Introduction One of the most overlooked side effects of rapid weight loss on GLP-1 medications is muscle loss. When the weight comes off fast — as it often does on Ozempic — not all of it is fat. Studies published in 2025-2026 indicate that a meaningful portion of the weight lost on GLP-1 agonists can come from lean body mass, not just fat. This is a problem. Muscle isn’t just for looking toned — it’s your metabolic engine. Less muscle means a slower metabolism, which makes long-term weight maintenance harder. It also increases your risk of frailty, falls, and metabolic disease as you age. ...

Introduction Getting your Ozempic dose right is one of the most important factors in your weight loss journey. Start too fast and the side effects can be unbearable. Move too slow and you might wonder if the medication is even working. By 2026, with millions of patients using semaglutide for weight loss, dosing protocols have been refined with real-world data from clinical practice — not just clinical trials. This guide covers everything you need to know about Ozempic dosing: from the starting dose to maximum doses, how titration works, what to do if you miss a dose, and how to balance effectiveness with tolerability. ...

Introduction If you’re starting Ozempic (semaglutide) — or considering it — you’ve probably heard about the side effects. And they’re real. But understanding what’s normal, what’s manageable, and what’s a red flag can make the difference between a successful treatment journey and giving up too soon. This guide draws on peer-reviewed clinical trials, FDA adverse event data, and real patient experiences to give you the clearest picture available in 2026. ...

Introduction The two heavyweight champions of GLP-1 weight loss — Ozempic (semaglutide) and Mounjaro (tirzepatide) — dominate the conversation in 2026. But which one should you choose? This comparison is based on head-to-head clinical trials, real-world data, and 2026 pricing and insurance information. We’ll cover effectiveness, side effects, cost, and practical considerations to help you make an informed decision with your doctor. Quick Comparison: At a Glance Feature Ozempic (Semaglutide) Mounjaro (Tirzepatide) Drug Class GLP-1 receptor agonist Dual GIP/GLP-1 receptor agonist Manufacturer Novo Nordisk Eli Lilly FDA Approved For Type 2 diabetes (2017); Weight loss as Wegovy (2021) Type 2 diabetes (2022); Weight loss as Zepbound (2023) Dosing Frequency Once weekly Once weekly Max Dose for Weight Loss 2.4 mg (Wegovy) 15 mg (Zepbound) Average Weight Loss at Max Dose ~15% of body weight ~21-23% of body weight Administration Prefilled pen Single-dose pen (autoinjector) Effectiveness: Mounjaro Wins — But by How Much? The SURMOUNT-1 Trial (Mounjaro/Zepbound) In the landmark SURMOUNT-1 trial, participants taking the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks. At the 10 mg dose, average weight loss was 21.4%. ...